Brain damage estimated by MRI partially correlates with clinical measures in MS patients. To assess wheter PET may better determine the impact of MS lesions on brain function, we evaluated 8 MS patients clinically, neuropsycologically, by MRI, and by quantitative 18F-DG. The rCMRglc values from individual MS patients were compared to a group of 7 healthy subjects (/-score analysis). In MS patients, cognitive, motor, and cerebellar impairments were paralleled, respectively, by a global rCMRglc decline or by selective decreses in basal ganglia and cerebellum. No correlation was found between the extent of white matter hyperintensities on MRI sequences and extent of metabolic abnormalities. Our data suggest that 18F-DG PET may be a good tool to quantify brain function in MS patients The correlation between metabolic and clinical characteristics may suggest the use of 18F-DG PET to assess the efficacy of experimental therapeutics.
|Number of pages||1|
|Journal||Italian Journal of Neurological Sciences|
|Publication status||Published - 1997|
ASJC Scopus subject areas
- Clinical Neurology